Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1607054 | 0.94 | NOS3 (0.41) | NOS3NOS2LMNATSHRKDM4E | |
| SCHEMBL8551454 | 0.84 | — | — | |
| SCHEMBL498606 | 0.73 | MAPT (0.47) | LMNATSHRKDM4EHTTALDH1A1 | |
| SCHEMBL1607736 | 0.73 | NOS2 (0.39) | NOS3NOS2TSHRKDM4EHTT | |
| SCHEMBL1606746 | 0.71 | NOS3 (0.38) | NOS3NOS2TSHRKDM4EHTT | |
| SCHEMBL663162 | 0.71 | MAPT (0.46) | LMNATSHRKDM4EHTTRORC | |
| SCHEMBL930295 | 0.71 | MAPT (0.46) | LMNATSHRKDM4EHTTRORC | |
| SCHEMBL7122480 | 0.70 | MAPT (0.44) | LMNATSHRKDM4EHTTRORC | |
| SCHEMBL8133890 | 0.69 | — | — | |
| SCHEMBL1364757 | 0.68 | MAPT (0.43) | NOS3NOS2TSHRKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275984-A1 | Novel Thieno-Pyridine and Thieno-Pyrimidine Derivatives and Their Use as Positive Allosteric Modulators of Mglur2-Receptors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-29 | — | — | US | claimed |
| US-8518975-B2 | Gamma secretase modulators | Merck Sharp + Dohme Corp. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8217570-B2 | Anthracene derivative and organic electroluminescent element using the same | IDEMITSU KOSAN CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110082153-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-04-07 | — | — | US | disclosed |
| EP-2200990-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009032277-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20080111473-A1 | Anthracene Derivative and Organic Electroluminescent Element Using the Same | IDEMITSU KOSAN CO., LTD. (JP) | 2008-05-15 | — | — | US | disclosed |
| US-4150129-A | DIURETICS, HYPOTENSIVES | CIBA-GEIGY CORPORATION (US) | 1979-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082153-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | NOS3 4452/4885NOS2 4563/4885LMNA 1968/4885 |
| US-20070275984-A1 | Novel Thieno-Pyridine and Thieno-Pyrimidine Derivatives and Their Use as Positive Allosteric Modulators of Mglur2-Receptors | GRM2, GRIA2, GRM1 | NOS3 4106/4885NOS2 2994/4885LMNA 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.